OVERVIEW {#sec1-1}
========

The convergence of conventional pharmaceutical industry with the modern digital technologies is set to open a whole new set of opportunities. Modern pharmacotherapeutic significantly improvises on existing approaches for improving and maintaining the health of the patients. However, controlling the cost of health care poses a major challenge for the governments across the globe.\[[@ref1]\] Digital health-care technologies can contribute to reducing the health-care costs and improve the treatment outcome, especially for lifestyle and chronic diseases.\[[@ref2]\] The burden of chronic diseases in terms of morbidity and finances, more so for the developing world, is enormous. A testimony to this is the fact that the U.S. spends 86% of all the health care on chronic diseases every year, and approximately half of the American population are suffering from diseases such as diabetes, heart diseases, obesity, hypertension, smoking, and chronic respiratory disorders.\[[@ref3]\] Developing countries such as India and China also have the highest incidence of Type 2 diabetes in the world.\[[@ref4]\] Therefore, embarking on digital technologies in the health-care industry can prove to be a shot in the arm for further improving the health of the community.

INTRODUCTION {#sec1-2}
============

Sean Duffy, CEO of Omada Health, first used "Digital Therapeutics" (DT) in 2013 to describe its online coaching software to help prediabetics avoid getting sick by exercising more and losing weight.\[[@ref5]\] DT is defined as "a health discipline and treatment option that utilizes digital and online health technologies to treat a medical or psychological condition."\[[@ref6]\] They are technology-based solutions in the form of tools such as smartphone applications (app), wearable devices (tracking sensors), web-based studies, social networks, behavioral science, and telemedicine platforms to monitor patient activity and social interaction to detect and intervene when required.\[[@ref7]\] [Table 1](#T1){ref-type="table"} highlights the difference between digiceuticals and wellness tracking applications.

###### 

Difference between digital therapeutics and wellness tracking applications

  Category                     DTs                                                                                   Wellness tracking applications
  ---------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Indication                   Focused on one condition mostly                                                       Focused on various condition
  Prerequisite                 Regulatory requirement like multicenteric RCTs among target population                Minimal technical requirement for downloading from application store
  Therapeutic claim            Safe and proven therapeutic value by collection and analysis of real-world evidence   Unsubstantiated claims about clinical benefits
  Mode of access               B2B2C                                                                                 B2C
  Key performance indicators   Compliance                                                                            Number of users
                               Prevention of readmission or                                                          Usage
                               Repeat intervention in a given amount of time                                         Direct turnover
  Reimbursement claim          It can be reimbursed by payers depending on DT compliance                             It can only be subscribed by consumers.

B2C=Business-to-consumer, B2B2C=Business to B2C, RCTs=Randomized controlled trials, DTs=Digital therapeutics

DT can claim clinical benefits in three ways:\[[@ref8]\]

Digital services {#sec2-1}
----------------

They modify patient behavior and help in driving a clinical outcome, for example, Omada health\'s digital behavior platform for weight loss.

Adjunctive digital therapeutics {#sec2-2}
-------------------------------

This tier complements traditional therapeutics, indirectly improving the clinical outcome, for example, Proteus Digital Health\'s Discover medication.

Digital drug replacement {#sec2-3}
------------------------

They substitute conventional medicine. This requires stringent criteria in terms of clinical trials and the Food and Drug Administration (FDA) review, for example, reSET application for treating substance abuse disorder.

A host of companies are collaborating with health-care providers to shape up various DT programs in different diseases. Most of these initiatives are currently US based, but emerging trends from countries such as Japan, UK, and India are a positive development \[[Table 2](#T2){ref-type="table"}\].

###### 

List of various digital therapeutic programs running across the world

  Program name              Company                 Origin   Domain
  ------------------------- ----------------------- -------- ------------------------------------------------------------
  DCP                       Omada                   US       Prediabetics, type-2 DM, hypertension, high cholesterol
  Blue Star                 Welldoc                 US       Type-2 DM
  Virta                     Virta Health            US       Type- 2 DM
  Discover Abilify Mycite   Proteus                 US       Ingestible sensors
  reSET                     Pear Therapeutics       US       Substance abuse
  reSET-O                   Pear Therapeutics       US       Opioid disorders
  Thrive                    Better Therapeutics     US       Type-2 DM, CHD/CAD, chronic conditions
                            Big Health              US       Mental health
                            Headspace               US       Stress, insomnia
                            IQVIA                   US       Health-care technology and clinical research collaboration
                            Kaja Heath              US       Chronic back pain
                            Livongo                 US       Prediabetics, type-2 DM, HTN
                            Merck innovation fund   US       Venture capital fund
                            Mount Sinai             US       Health-care system
                            NHS                     UK       Checkup for stroke, kidney disease, type-2 DM, CAD
                            Otsuka                  Japan    Digital pill aripiprazole with Proteus
                            Propeller Health        US       Digital management of asthma/COPD
  mySugr                    Roche                   US       Type-2 DM, mental health program
                            Solera                  US       Type-2 DM/chronic diseases
                            Xealth                  US       Digital analysis platform
  ALKTO1                    Akili Interactive       US       ADHD, autism, depression
  PT PAL                                                     Rehabilitation and care
  My fitness                                                 Food intake and calories
  Stop cannabis                                              Cannabis addiction
  Asthma MD                                                  Asthma
  Workit Health                                              Addictions
  Be safe                                                    Preventing suicide

DCP=Dynamic control programme, DM=Diabetes mellitus, HTN=Hypertension, CHD=Coronary heart disease, CAD=Coronary artery disease, COPD=Chronic obstructive pulmonary disease

KEY MILESTONES IN DIGITAL THERAPEUTICS {#sec1-3}
======================================

Digital prescription program (June 2013) {#sec2-4}
----------------------------------------

It was launched by WellDoc with an aim to help diabetic patients manage their condition using a mobile app. Blue Star was the first digital phone app approved by the FDA to manage diabetes.\[[@ref9]\]

Diabetes prevention program {#sec2-5}
---------------------------

It is a lifestyle modification program for diabetes prevention clinically proven to be more efficacious then lifestyle modifications launched by Omada Health, Canary Health, and Blue Mesa Health. It includes close monitoring of patients in terms of diet, weight, and physical activity and associates them with health coaches, clinicians, or peer groups. This helps to intervene at the time of exacerbations and reduce the frequency of symptoms.\[[@ref9]\]

Program aimed to curb substance abuse disorder {#sec2-6}
----------------------------------------------

ReSET application developed by Pear therapeutics.\[[@ref10]\] It is a prescription DT used in conjugation with the standard treatment. It claims to improve clinical outcome by increasing patient\'s adherence to treatment.

Various DT initiatives are currently underway for a host of diseases:

Asthma {#sec2-7}
------

Asthma was launched by propeller health partnered with GlaxoSmithKline. It consists of a sensor attached with an inhaler to monitor usage and provide feedback. It is used along with medicines and claims that medication needed by the patients is less.

Schizophrenia {#sec2-8}
-------------

Thrive digital app launched by Pear therapeutics.\[[@ref11]\] It is used along with antipsychotic medication and targets positive symptoms of schizophrenia.

Insomnia {#sec2-9}
--------

An online therapy program called Sleepio was launched by Big Health which involves visual exercises to induce sleep. It claims to replace sleeping pills, being more efficacious and cost-effective.

Heart disease {#sec2-10}
-------------

A physician approved nutritional and lifestyle plan that guides patients to improve their health states launched by Suggestive therapeutics. It monitors physical activity, heart rate, and rhythm.\[[@ref12]\]

Stress incontinence {#sec2-11}
-------------------

"INNOVO" is the first transcutaneous electrical stimulator launched by Atlantic therapeutics in women to treat stress urinary incontinence. It offers a safe, clinically effective, and noninvasive choice.\[[@ref13]\]

Various stakeholders involved in the development of DT are depicted in [Figure 1](#F1){ref-type="fig"}.

![Various stakeholders involved in digital therapeutics](PCR-11-54-g001){#F1}

THERAPEUTIC BENEFICIARIES OF DIGITAL THERAPEUTICS {#sec1-4}
=================================================

Chronic debilitating diseases related to behavior can be immediate beneficiaries for DT. Usually, cognitive behavior therapy is a significant component of their treatment. DTs can offer a solution in terms of a mixture of prevention and therapeutic value. For example, in patients of Alzheimer disease which are expected to rise due to aging population and increased diagnostic awareness, DTs can be very fruitful.\[[@ref14]\] Round the clock, monitoring of bipolar and depression patients can improve their quality of life, as psychiatrists cannot monitor a patient 24 h a day. Such technologies can be helpful in bringing a behavioral change among smokers and alcoholics.\[[@ref15]\] These tools have shown a positive impact in patients of HIV and sexually transmitted infections in terms of acceptance.\[[@ref16]\] Various applications have been made for efficient and timely management of perioperative patients.\[[@ref17]\] Feasibility of these technologies in modern clinical practice clinics, for example, clinical surgery and rehabilitation, is also upcoming.\[[@ref18]\] [Table 3](#T3){ref-type="table"} highlights advantages and disadvantages of DT.\[[@ref3]\]

###### 

Advantages and disadvantages of digital therapeutics

  Advantages                                                                                                  Disadvantages
  ----------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
  No toxicity and other associated side effects                                                               Compromised patient privacy
  Direct access to patients                                                                                   Legal liability for injuries
  Minimizes costs associated with attending hospital or doctor's clinic                                       Cross-jurisdictional practice of medicine
  Minimizes time in administrative tasks and routine communication and more time spent on treating patients   Serious mistake while using DT might affect thousands of patients at a time without ready mechanisms for detection and correction
  More efficacious as ensures continuous monitoring of patient vitals                                         Some applications cannot guarantee the accuracy of the diagnosis
  Encourages adherence to healthy lifestyle behavior and prescribed medications                               Some applications might give false claims which are designed without scientific input of medical professionals
  Opportunity to pair them with proven medications                                                            Cybersecurity of patient's data is a big responsibility for the DT companies
  Increases ways to interact with and empower patients                                                        

DT=Digital therapeutic

OPPORTUNITIES FOR DEVELOPERS CAN BE LEVERAGED INTO TWO PRIMARY WAYS {#sec1-5}
===================================================================

Explicit: Revenue from product/digital therapeutics {#sec2-12}
---------------------------------------------------

Some DTs such as WellDoc\'s Blue Star and Pear Therapeutics\' reSET can be reimbursed through insurance depending on the medical benefit they offer. DT manufactures can give license to other interested manufacturers and also there is opportunity of selling data to the same therapeutic field manufacturers for their future development of products.\[[@ref8]\]

Implicit: Nonrevenue benefits from digital therapeutics {#sec2-13}
-------------------------------------------------------

Through the collection of proprietary data source and its use in training, input and feedback through artificial intelligence offers unique competitive advantage. Collection of data through DT helps in executing innovative contracts and presentations of clinical effectiveness data to payers. It can be used as a pilot-runs offering before fully covering it by payers. Manufactures also can claim real-world evidence value of their DTs to payers. The life cycle of the DT can be updated rapidly through regular software updates and this can be utilized effectively during their sales pitches.\[[@ref8]\]

STEPS TAKEN BY US FOOD AND DRUG ADMINISTRATION {#sec1-6}
==============================================

Approval of the reSET application (1^st^ mobile App) for substance abuse disorder through the *de novo* premarket review pathway. Furthermore, reSET-O application for opioid use, schizophrenia, and anxiety disorderThe FDA is running a Pre-Cert Pilot Program for developing digital health-care technologiesIn 2018, 12 health-care algorithms using Artificial Intelligence software received FDA clearance\[[@ref19]\]FDA\'s Center for Devices and Radiological Health has established the Digital Health Program which fosters collaboration, enhances outreach to digital health customers, and develops and implements regulatory strategies\[[@ref20]\]The "Digital Health Innovation Action Plan" has been issued which ensures all Americans to have timely access to high-quality, safe, and effective digital health products.\[[@ref20]\]

SCOPE OF DIGITAL THERAPEUTICS IN INDIA {#sec1-7}
======================================

DT can play a vital role in India where universal health care is a challenge, but the use of digital tools is increasing at the same time. Rather than focusing on treatment of chronic diseases, there is a growing need to monitor unhealthy lifestyle behavior. Furthermore, in a country where an unmanageable doctor-to-patient ratio is a big hurdle, adopting technology to collect data will help prescribers to get more time in discussing solutions to patient problems. Regulatory obstacles should be addressed by the Central Drugs Standard Control Organization (CDSCO) to implement DT in India.

ROADBLOCKS IN DIGITAL THERAPEUTICS {#sec1-8}
==================================

Distinguishing DT from health and well-being market is needed when thousands of health applications are running worldwideRegulatory preparedness as only DT initiatives entail regulatory approvalIncentivization and Affordability: DT companies need to find ways of working in health-care ecosystem to align incentives between pharmaceutical companies, beneficiaries, and health-care providersEducation and technology adjustment for the patients to DT when issues of adherence and compliance are widespread in conventional therapeuticsTo promote the development of research program for DT, it is necessary to offer incentives to researchers for addressing unmet medical needs.

CONCLUSION {#sec1-9}
==========

DT is an emerging field of medicine in the overburdened health systems. Clinical trials are a must to prove their credibility. If used judiciously, they can even improve the treatment outcome. DT can provide safer and less expensive options than traditional treatment, which, in turn, can save billions of dollars in health care, especially in chronic and behavioral disorders. Regulatory authorities are also acknowledging their potential. Policy-makers need to make DT more readily available to the patients by ensuring adequate verification and reproducibility and educating health-care providers and patients regarding the advantages of DT. From mobile medical apps and fitness trackers to software that supports the clinical decisions which doctors make everyday, digital technology can turn out to be a revolution toward affordable health care worldwide.
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